Skip to content

Sixty seconds on . . . psilocybin

Nigel Hawkes

BMJ May 18, 2016 DOI: 10.1136/bmj.i2775 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational study Peer reviewed
Population Patients with treatment-resistant depression
Intervention Psilocybin
Duration Three-month follow-up
Topics Psilocybin
Keywords Magic telescope Depression economics Psychoanalysis Hallucinogen Psychotherapist Keynesian economics
Citations 5
Key findings Psilocybin may be effective against treatment-resistant depression, with over 40% of patients in remission three months after treatment.

Abstract

Not so fast. There’s a long way to go. But a study in London has shown that the active ingredient in magic mushrooms, psilocybin, may be effective against treatment resistant depression. Its effects were quick—within a week—and more than 40% of the patients treated were still in remission three months later.1 Yes, as far as it goes. These were people whose depression had …

Comparable studies

Other observational and cohort studies on psilocybin, most cited first.

Study Year Design Participants
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Patients with treatment-resistant depression 2017 Observational cohort n = 19
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels Healthy volunteers 2019 Observational cohort n = 8
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin Humans 2017 Observational study
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. USA adult respondents from the National Survey on Drug Use and Health (2008-2012) 2015 Observational cohort n = 190,000
Prediction of Psilocybin Response in Healthy Volunteers Healthy volunteers 2012 Observational cohort n = 409

Explore topics